Posted by Michael Wonder on 01 Mar 2023
Kevzara (sarilumab) approved by FDA as first and only biologic indicated for patients with polymyalgia rheumatica
28 February 2023 - Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial.
Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has approved Kevzara (sarilumab) for the treatment of polymyalgia rheumatica, an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
